CUDA

CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively[1]. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease[2].

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Cell Cycle/DNA Damage >> PPAR

PPARα

mouse sEH:11.1 nM (IC50)

human sEH:112 nM (IC50)

CUDA (10 μM; 18 hours) produces 6- and 3-fold increases of PPARalpha in COS-7 cells[2]. CUDA does not alter PPARalpha protein expression, and it competitively inhibits the binding of Wy-14643 (pirinixic acid) to the ligand binding domain of PPARalpha, suggesting that it functions as a PPARalpha ligand[2]. Western Blot Analysis[2] Cell Line: COS-7 cells Concentration: 10 μM Incubation Time: 18 hours Result: Activated PPARα by binding to the ligand binding domain of PPARα.

[1]. Morisseau C, et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol. 2002 May 1;63(9):1599-608.

[2]. Fang X, et al. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther. 2005 Jul;314(1):260-70.